- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Thousand Oaks Today
By the People, for the People
Highline Wealth Partners Trims Amgen Stake
Institutional investor reduces position in biotech giant by 96%
Apr. 1, 2026 at 11:22am
Got story updates? Submit your updates here. ›
Highline Wealth Partners LLC, an investment management firm, has decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 96% during the fourth quarter, according to a recent filing with the Securities and Exchange Commission. The fund now owns just 167 shares of the medical research company's stock, down from 4,171 shares previously.
Why it matters
Amgen is one of the largest and most influential biotechnology companies, developing critical drugs for cancer, kidney disease, and other serious illnesses. Institutional investors closely monitor changes in ownership of Amgen stock, as it can signal broader market trends or shifts in sentiment around the company.
The details
According to the SEC filing, Highline Wealth Partners sold 4,004 shares of Amgen stock during the fourth quarter, reducing its total position to just 167 shares valued at $55,000 as of the most recent reporting period. The firm cited portfolio rebalancing and a shift in investment strategy as the reasons for the dramatic reduction in its Amgen holdings.
- Highline Wealth Partners filed the disclosure on April 1, 2026.
- The trades occurred during the fourth quarter of 2025.
The players
Highline Wealth Partners LLC
An investment management firm that has decreased its position in Amgen Inc. by 96% over the past quarter.
Amgen Inc.
A global biotechnology company that develops and markets medicines to treat serious illnesses, including cancer, kidney disease, and cardiovascular conditions.
The takeaway
This reduction in Highline Wealth Partners' Amgen holdings, while relatively small in the grand scheme of Amgen's ownership structure, could signal a broader shift in investor sentiment around the biotech industry or the company's near-term prospects. However, Amgen remains a dominant force in its field, and institutional investors will likely continue to closely monitor changes in its shareholder base.
